Texas A&M Signs Letter of Intent to Collaborate on War Wound Healing With DermaPlus and MatrixDesign
NEW YORK--(BUSINESS WIRE)--Texas A&M University announces scientists at both the Bioseparations Lab of Biological and Agricultural Engineering Department and the Institute for Plant Genomics and Biotechnology have signed a Letter of Intent to collaborate with DermaPlus, Inc. and MatrixDesign, Inc. on the University’s War Wound Healing and Tissue Regeneration Project. The research collaborations are directed toward improving the quality and availability of human Tropoelastin (Elastotropin®) when used to heal battlefield injuries. DermaPlus and MatrixDesign will provide funding and research materials.
Martin B. Dickman, Ph.D. and Director of the Institute for Plant Genomics and Biotechnology at Texas A&M, and Zivko L. Nikolov, Ph.D. a Dow Professor from the Texas A&M Biological and Agricultural Engineering Department will collaborate with Burt Ensley, PhD. Microbiologist, CEO of DermaPlus and COB of MatrixDesign. Drs. Dickman and Nikolov are with the College of Agriculture and Life Sciences.
Burt Ensley, Ph.D. states, “Along with Drs. Dickman and Nikolov, we plan to further develop the proven abilities of human Tropoelastin (Elastotropin®) to penetrate the deepest parts of the topmost layer of skin. Elastotropin® is already very successfully used to reduce and help prevent facial and eye wrinkles in the DermaLastyl skin care line of products. Elastatropin® was developed in response to DARPA’s tissue regeneration competition, we now expect to create Medical Device solutions that help regenerate tissue and accelerate wound healing.”
Martin B. Dickman, Ph.D. notes, “This is a unique opportunity for the Institute to explore avenues that utilize the power of plant biotechnology to further develop human Tropoelastin (Elastatropin®) and address the hundreds of soldiers that need accelerated healing of wounds and scars.”
Zivko L. Nikolov, Ph.D. comments, “Human Tropoelastin (Elastatropin®) is a difficult molecule to efficiently produce and purify in sufficient quantities at a reasonable cost. The Bioseparations lab is excited to tackle these bioprocessing challenges and contribute to the design of the next generation of cost-effective wound care, scar healing, and tissue regeneration ingredients.”
About DermaPlus, Inc.
DermaPlus, Inc., the producer of the DermaLastyl line of products, is a Biotechnology company that designs and manufactures sophisticated, high performance biomaterials for use in the cosmeceutical and personal care markets. Based on human genetic sequences, these biomaterials can be customized to reflect the genetic makeup of human tissues, population groups or even single individuals. DermaLastyl-B and DermaLastyl-E are the first genetically engineered products on the market that help restore elastic properties to the skin and around the eyes. Used properly, DermaLastyl will reduce the need for Botox or cosmetic surgery and extend the life of previous procedures.
DermaLastyl-B face cream and DermaLastyl-E eye cream are available only at
dermalastyl.com
and
800-335-8312 |
